

World Journal of *Clinical Cases*

World J Clin Cases 2022 September 6; 10(25): 8808-9179



MINIREVIEWS

- 8808** Ear, nose, and throat manifestations of COVID-19 and its vaccines
Al-Ani RM
- 8816** Potential influences of religiosity and religious coping strategies on people with diabetes
Onyishi CN, Eseadi C, Itechukwu LC, Okoro KN, Okolie CN, Egbule E, Asogwa E

ORIGINAL ARTICLE**Case Control Study**

- 8827** Effectiveness of six-step complex decongestive therapy for treating upper limb lymphedema after breast cancer surgery
Zhang HZ, Zhong QL, Zhang HT, Luo QH, Tang HL, Zhang LJ

Retrospective Study

- 8837** Hospital admissions from alcohol-related acute pancreatitis during the COVID-19 pandemic: A single-centre study
Mak WK, Di Mauro D, Pearce E, Karran L, Myintmo A, Duckworth J, Orabi A, Lane R, Holloway S, Manzelli A, Mossadegh S

- 8844** Indocyanine green plasma clearance rate and ^{99m}Tc-galactosyl human serum albumin single-photon emission computed tomography evaluated preoperative remnant liver
Iwaki K, Kaihara S, Kita R, Kitamura K, Hashida H, Uryuhara K

- 8854** Arthroscopy with subscapularis upper one-third tenodesis for treatment of recurrent anterior shoulder instability independent of glenoid bone loss
An BJ, Wang FL, Wang YT, Zhao Z, Wang MX, Xing GY

- 8863** Evaluation of the prognostic nutritional index for the prognosis of Chinese patients with high/extremely high-risk prostate cancer after radical prostatectomy
Yang F, Pan M, Nie J, Xiao F, Zhang Y

Observational Study

- 8872** Chlorine poisoning caused by improper mixing of household disinfectants during the COVID-19 pandemic: Case series
Lin GD, Wu JY, Peng XB, Lu XX, Liu ZY, Pan ZG, Qiu ZW, Dong JG

- 8880** Mental health of the Slovak population during COVID-19 pandemic: A cross-sectional survey
Kralova M, Brazinova A, Sivcova V, Izakova L

Prospective Study

- 8893** Arthroscopic anatomical reconstruction of lateral collateral ligaments with ligament advanced reinforcement system artificial ligament for chronic ankle instability
Wang Y, Zhu JX

SYSTEMATIC REVIEWS

- 8906** How to select the quantitative magnetic resonance technique for subjects with fatty liver: A systematic review
Li YW, Jiao Y, Chen N, Gao Q, Chen YK, Zhang YF, Wen QP, Zhang ZM
- 8922** Lymphocytic choriomeningitis virus: An under-recognized congenital teratogen
Ferenc T, Vujica M, Mrzljak A, Vilibic-Cavlek T

CASE REPORT

- 8932** Alagille syndrome associated with total anomalous pulmonary venous connection and severe xanthomas: A case report
Zeng HS, Zhang ZH, Hu Y, Zheng GL, Wang J, Zhang JW, Guo YX
- 8939** Colo-colonic intussusception with post-polypectomy electrocoagulation syndrome: A case report
Moon JY, Lee MR, Yim SK, Ha GW
- 8945** Portal vein gas combined with pneumatosis intestinalis and emphysematous cystitis: A case report and literature review
Hu SF, Liu HB, Hao YY
- 8954** Quadricuspid aortic valve and right ventricular type of myocardial bridging in an asymptomatic middle-aged woman: A case report
Sopek Merkaš I, Lakušić N, Paar MH
- 8962** Treatment of gastric carcinoma with lymphoid stroma by immunotherapy: A case report
Cui YJ, Ren YY, Zhang HZ
- 8968** Gallstone associated celiac trunk thromboembolisms complicated with splenic infarction: A case report
Wu CY, Su CC, Huang HH, Wang YT, Wang CC
- 8974** Extracorporeal membrane oxygenation for lung cancer-related life-threatening hypoxia: A case report
Yoo SS, Lee SY, Choi SH
- 8980** Multi-disciplinary treatment of maxillofacial skeletal deformities by orthognathic surgery combined with periodontal phenotype modification: A case report
Liu JY, Li GF, Tang Y, Yan FH, Tan BC
- 8990** X-linked recessive Kallmann syndrome: A case report
Zhang P, Fu JY
- 8998** Delayed complications of intradural cement leakage after percutaneous vertebroplasty: A case report
Ma QH, Liu GP, Sun Q, Li JG

- 9004** Coexistent Kaposi sarcoma and post-transplant lymphoproliferative disorder in the same lymph nodes after pediatric liver transplantation: A case report
Zhang SH, Chen GY, Zhu ZJ, Wei L, Liu Y, Liu JY
- 9012** Misdiagnosis of pancreatic metastasis from renal cell carcinoma: A case report
Liang XK, Li LJ, He YM, Xu ZF
- 9020** Discoid medial meniscus of both knees: A case report
Zheng ZR, Ma H, Yang F, Yuan L, Wang GD, Zhao XW, Ma LF
- 9028** Simultaneous laparoscopic and arthroscopic excision of a huge juxta-articular ganglionic cyst compressing the sciatic nerve: A case report
Choi WK, Oh JS, Yoon SJ
- 9036** One-stage revision arthroplasty in a patient with ochronotic arthropathy accompanied by joint infection: A case report
Wang XC, Zhang XM, Cai WL, Li Z, Ma C, Liu YH, He QL, Yan TS, Cao XW
- 9044** Bladder paraganglioma after kidney transplantation: A case report
Wang L, Zhang YN, Chen GY
- 9050** Total spinal anesthesia caused by lidocaine during unilateral percutaneous vertebroplasty performed under local anesthesia: A case report
Wang YF, Bian ZY, Li XX, Hu YX, Jiang L
- 9057** Ruptured splenic artery aneurysms in pregnancy and usefulness of endovascular treatment in selective patients: A case report and review of literature
Lee SH, Yang S, Park I, Im YC, Kim GY
- 9064** Gastrointestinal metastasis secondary to invasive lobular carcinoma of the breast: A case report
Li LX, Zhang D, Ma F
- 9071** Post-bulbar duodenal ulcer with anterior perforation with kissing ulcer and duodenocaval fistula: A case report and review of literature
Alzerwi N
- 9078** Modified orthodontic treatment of substitution of canines by first premolars: A case report
Li FF, Li M, Li M, Yang X
- 9087** Renal cell carcinoma presented with a rare case of icteric Stauffer syndrome: A case report
Popov DR, Antonov KA, Atanasova EG, Pentchev CP, Milatchkov LM, Petkova MD, Neykov KG, Nikolov RK
- 9096** Successful resection of a huge retroperitoneal venous hemangioma: A case report
Qin Y, Qiao P, Guan X, Zeng S, Hu XP, Wang B
- 9104** Malignant transformation of biliary adenofibroma combined with benign lymphadenopathy mimicking advanced liver carcinoma: A case report
Wang SC, Chen YY, Cheng F, Wang HY, Wu FS, Teng LS

- 9112 Congenital hepatic cyst: Eleven case reports
Du CX, Lu CG, Li W, Tang WB
- 9121 Endovascular treatment of a ruptured pseudoaneurysm of the internal carotid artery in a patient with nasopharyngeal cancer: A case report
Park JS, Jang HG
- 9127 Varicella-zoster virus meningitis after spinal anesthesia: A case report
Lee YW, Yoo B, Lim YH
- 9132 Chondrosarcoma of the toe: A case report and literature review
Zhou LB, Zhang HC, Dong ZG, Wang CC
- 9142 Tamsulosin-induced life-threatening hypotension in a patient with spinal cord injury: A case report
Lee JY, Lee HS, Park SB, Lee KH
- 9148 CCNO mutation as a cause of primary ciliary dyskinesia: A case report
Zhang YY, Lou Y, Yan H, Tang H
- 9156 Repeated bacteremia and hepatic cyst infection lasting 3 years following pancreatoduodenectomy: A case report
Zhang K, Zhang HL, Guo JQ, Tu CY, Lv XL, Zhu JD
- 9162 Idiopathic cholesterol crystal embolism with atheroembolic renal disease and blue toes syndrome: A case report
Cheng DJ, Li L, Zheng XY, Tang SF
- 9168 Systemic lupus erythematosus with visceral varicella: A case report
Zhao J, Tian M

LETTER TO THE EDITOR

- 9176 Imaging of fibroadenoma: Be careful with imaging follow-up
Ece B, Aydin S

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Mohsen Khosravi, MD, Assistant Professor, Department of Psychiatry and Clinical Psychology, Zahedan University of Medical Sciences, Zahedan 9819713955, Iran. m.khosravi@zaums.ac.ir

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases (WJCC, World J Clin Cases)* is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The *WJCC* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for *WJCC* as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The *WJCC*'s CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Xu Guo*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lei Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

September 6, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

Tamsulosin-induced life-threatening hypotension in a patient with spinal cord injury: A case report

Jae Young Lee, Ho Seok Lee, Si-Bog Park, Kyu Hoon Lee

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: Dai DL, China; Ichihara K, Japan; Wang G, China

Received: April 19, 2022

Peer-review started: April 19, 2022

First decision: May 30, 2022

Revised: June 8, 2022

Accepted: July 22, 2022

Article in press: July 22, 2022

Published online: September 6, 2022



Jae Young Lee, Ho Seok Lee, Si-Bog Park, Kyu Hoon Lee, Rehabilitation Medicine, Hanyang University Hospital, Seoul 04763, South Korea

Corresponding author: Kyu Hoon Lee, MD, PhD, Professor, Rehabilitation Medicine, Hanyang University Hospital, No. 222-1 Wangsimni-ro, Seongdong-Gu, Seoul 04763, South Korea. dumitru1@hanyang.ac.kr

Abstract

BACKGROUND

Tamsulosin, a selective α_1 -adrenergic receptor antagonist, is commonly used for treating neurogenic bladder in patients with spinal cord injury (SCI). No severe adverse events have been described with such tamsulosin use. To our knowledge, we report the first case of severe life-threatening hypotension as an adverse effect of tamsulosin in a person with SCI. Therefore, we report this case to inform that this severe adverse effect of tamsulosin can occur when treating patients with SCI.

CASE SUMMARY

A 59-year-old woman was diagnosed with cervical spinal cord myelopathy and was classified as American Spinal Injury Association Impairment Scale D, neurological level of injury C3. Because she suffered from voiding difficulty due to neurogenic bladder, we prescribed tamsulosin. Her vital signs remained stable, but occasional hypotensive symptoms followed defecation. We reduced the dose of tamsulosin, but after administering tamsulosin for 9 d, she experienced life-threatening hypotension with no evidence of hypovolemic shock, neurogenic shock, cardiogenic shock, or septic shock. A hypotensive condition induced by tamsulosin was the suspected cause, and her symptoms could be associated with adverse effects of tamsulosin. As symptoms resolved after stopping tamsulosin, and no other reason was found, we concluded that tamsulosin was the cause of her symptoms.

CONCLUSION

Caution for severe hypotension is needed when administering tamsulosin for neurogenic bladder in a patient with SCI.

Key Words: Tamsulosin; Neurogenic bladder; Spinal cord injury; Hypotension; Vasovagal symptoms; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Voiding difficulty is a common symptom of spinal cord injury (SCI) due to neurogenic bladder. Tamsulosin is commonly used for treating neurogenic bladder. However, this case demonstrated that tamsulosin can cause severe life-threatening hypotension. Thus, clinicians should be aware of this possible condition when treating neurogenic bladder in a patient with SCI.

Citation: Lee JY, Lee HS, Park SB, Lee KH. Tamsulosin-induced life-threatening hypotension in a patient with spinal cord injury: A case report. *World J Clin Cases* 2022; 10(25): 9142-9147

URL: <https://www.wjgnet.com/2307-8960/full/v10/i25/9142.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i25.9142>

INTRODUCTION

Tamsulosin is a selective $\alpha 1$ -adrenergic receptor antagonist that is widely used for benign prostatic hypertrophy (BPH). It also is effective against and commonly used for treating neurogenic bladder in patients with spinal cord injury (SCI). The usual dosage of tamsulosin is 0.2, 0.4, or 0.8 mg *per day*[1-3]. In Korea, tamsulosin is approved by insurance in both men and women who have neurogenic bladder as well as BPH. Furthermore, tamsulosin is an effective treatment for relief of lower urinary tract symptoms in women by improving the average flow rate and the residual volume after voiding[4,5].

Classically, $\alpha 1$ -adrenergic receptor antagonists have been used for treating arterial hypertension. Among the three $\alpha 1$ -adrenergic receptor subtypes ($\alpha 1A$, $\alpha 1B$, and $\alpha 1D$), $\alpha 1B$ is thought to have an effect on vasoconstriction. The $\alpha 1A$ -adrenergic receptor subtype is more specifically involved in the human prostate[1]. Tamsulosin is an $\alpha 1$ -adrenergic receptor antagonist with high selectivity for $\alpha 1A$ -adrenergic receptors and low selectivity for $\alpha 1B$ -adrenergic receptors.

Well-known adverse effects of tamsulosin are dizziness, abnormal ejaculation, and asthenia[3,6]. Hypotension is another possible but rare adverse event[1-3,6]. Previous cases of severe hypotension induced by tamsulosin were people with BPH or undergoing a general anesthetic procedure[6,7]. To the best of our knowledge, there are no reported cases of tamsulosin-induced severe hypotension in people with SCI. Here, we present a unique case of a woman with SCI who suffered life-threatening hypotension caused by tamsulosin.

CASE PRESENTATION

Chief complaints

A 59-year-old woman suffering from tetraparesis due to cervical spinal cord myelopathy presented with a sudden drop in blood pressure (BP) after tamsulosin use for 9 d.

History of present illness

A cervical spine magnetic resonance imaging (MRI) study was performed. The patient was diagnosed with cervical spinal cord myelopathy at the C3-C6 level and fractures at the C4-C6 level. She was classified as C3 AIS D (American Spinal Injury Association Impairment Scale). After surgery, she was transferred to the rehabilitation medicine department after Foley catheter insertion for urination.

Considering her completeness of injury (AIS D), we removed her Foley catheter to identify residual urine using clean intermittent catheterization (CIC). On the day of removal, she was able to self-void, but residual urine was in the range of 160-200 mL. On suspicion of voiding difficulty due to neurogenic bladder, a complication of her SCI, we scheduled a urodynamic study, but the patient refused due to discomfort. In the absence of a urodynamic study, we prescribed the recommended dose of 0.4 mg tamsulosin once daily[1,2]. For bladder management, we planned CIC at least 4 times/day, followed by self-voiding. Because she had been diagnosed with cervical spinal cord myelopathy, we encouraged a total fluid intake of approximately 2000 mL/day to prevent orthostatic hypotension[8].

After administering tamsulosin for 6 d, we reduced the dose to 0.2 mg once daily as her residual urine remained less than 200 mL. In addition to voiding difficulty, tamsulosin use produced other symptoms. Though her BP remained stable, she experienced occasional dizziness, likely due to orthostatic hypotension. She also experienced constipation and post-defecation symptoms such as nausea, lightheadedness, and sweating. We attributed these symptoms to orthostatic hypotension due to cervical myelopathy aggravated by tamsulosin[9]. We reduced the dose of tamsulosin to 0.2 mg and expect resolution of the symptoms.

After tamsulosin use for 9 d, her BP suddenly dropped to 70/40 mmHg. Before the event, she had difficulties defecating and experienced dizziness. Her heart rate was 50 beats/min (bpm), and body temperature (BT) was 36.3 °C, although there was no alteration in consciousness. Despite treatment with

normal saline hydration, supplemental O₂, and norepinephrine, her BP decreased to 50/40 mmHg. We did not suspect hypovolemia as the underlying cause and administered atropine for possible cardiogenic shock. However, her electrocardiogram (EKG) showed sinus bradycardia and vasovagal syncope as potential causes of her symptoms. After several minutes, her BP increased to 120/80 mmHg, and all other vital signs returned to within normal range, including BT. No abnormal result was found in her laboratory tests, including urinalysis. We stopped tamsulosin immediately because of its possible hypotensive effect.

On the next day, her BP dropped to 60/40 mmHg after defecation. Once again, she remained conscious and alert. Atropine was administered but had no effect. Norepinephrine was administered, her BP increased to 100/60 mmHg, and heart rate ranged from 90 to 110 bpm.

After the second event, there was no additional event of hypotension or difficulty in defecation after stopping tamsulosin.

History of past illness

The patient had a medical history of diabetes and hypertension and use of associated medications for the previous 20 years. Her BP and blood glucose level had been well-controlled. She had not experienced previous orthostatic hypotension or hypoglycemia.

Personal and family history

She had no family history of cervical cord disorder and other diseases.

Physical examination

Her motor strength was 3/5 grade in the upper extremities and 4/5 grade in the lower extremities. She suffered hypoesthesia below the C4 dermatome. Deep anal pressure and voluntary anal contraction were intact. According to physical examination, she was classified as C3 AIS D.

Laboratory examinations

Her blood glucose level was 74, 84, 94, 74, and 75 mg/dL pre-meal and 122, 133, 102, 106, and 140 mg/dL on 2 h after a meal. We did not examine hemoglobin A1c because we thought that her blood glucose level was well-controlled.

At the first hypotensive event, the laboratory test results showed white blood counts (WBC) of 8500/mm³, C-reactive protein (CRP) of 0.77 mg/dL, and procalcitonin of 0.04 ng/mL; troponin-I, lactate dehydrogenase, and creatinine levels were normal.

Imaging examinations

Cervical spine MRI revealed cord signal change at the C4-C6 levels in the emergency room (Figure 1). Chest and abdomen x-ray revealed no specific finding at the first hypotensive event (Figure 2).

FINAL DIAGNOSIS

As all symptoms resolved after stopping tamsulosin, we posited tamsulosin as the possible cause of her symptoms.


TREATMENT

We stopped tamsulosin immediately after her severe event. To treat possible sepsis, we administered piperacillin-tazobactam after laboratory tests including blood, urine, and stool cultures including that for *Clostridium difficile*. After 2 d, no bacterial growth was observed, and piperacillin-tazobactam was stopped. Norepinephrine was administered and tapered for 2 d.

OUTCOME AND FOLLOW-UP

At 4 d from the event, laboratory test results showed WBC of 5600/mm³, CRP of 5.0 mg/dL, and procalcitonin of 1.80 ng/mL. Her kidney function was normal, with a creatinine level of 0.60 mg/dL. There was no persistent difficulty in defecation.

We prescribed bethanechol chloride for voiding difficulty, and the patient was discharged 10 days after the first event[10,11].



DOI: 10.12998/wjcc.v10.i25.9142 Copyright ©The Author(s) 2022.

Figure 1 Cervical spine magnetic resonance imaging findings at admission. A: T2 sagittal image. Cord signal changes at C4-C6 levels were observed; B: T2 axial image at C4 level. Cord signal changes at C4 level are shown; C: T2 axial image at C5 level. Cord signal changes at C5 level and possible hematoma were observed; D: T2 axial image at C6 level. Cord signal changes at C6 level are shown.



DOI: 10.12998/wjcc.v10.i25.9142 Copyright ©The Author(s) 2022.

Figure 2 Chest X-ray at the first hypotensive event. No specific findings were revealed at the event.

DISCUSSION

At present, tamsulosin is widely used for voiding difficulty in patients with SCI. Although tamsulosin can affect BP, associated life-threatening hypotensive events are not common. One case report discusses tamsulosin-induced severe hypotension during general anesthesia[7]. Another documented increased risk of severe hypotension when administering tamsulosin to people with BPH[6]. However, there are no reported cases of tamsulosin-induced severe side effects in people with SCI.

In this case, the patient had two specific issues that commonly accompany cervical cord myelopathy: Orthostatic hypotension and difficulty in defecation. Her other medications included antidiabetics and an angiotensin receptor blocker for underlying hypertension. These medications have no reported significant effect when co-administered with tamsulosin[2]. As mentioned earlier, she had no evidence of hypovolemic, neurogenic, cardiogenic, or septic shock. Treatment with only normal saline hydration showed no benefit to her symptoms, and no evidence of dehydration was found. Cardiogenic shock was a possible cause since her BP increased after administering atropine at the first event. However, her EKG showed sinus bradycardia and no evidence of cardiogenic shock. Her response to atropine might have been due to vasovagal syncope. No microorganisms were found in culture before administration of antibiotics, and no evidence of infection was found. Although elevated CRP and procalcitonin (PCT) levels are common in septic conditions, those circumstances can be seen in other conditions, such as in anaphylactic shock[12]. Also, CRP and PCT levels can be increased by various etiologies other than infection[13]. Although autonomic dysreflexia is seen in SCI patients, she had experienced no prior acute hypertensive emergency and reported no noxious stimulus. Rather than autonomic dysreflexia, loss of sympathetic tone might have contributed to bradycardia or hypothermia. Therefore, a non-infectious and normal pathologic response was the suspected reason for her shock[14,15].

Tamsulosin and malignant vasovagal syncope remained possible causes of her life-threatening hypotension. However, vasovagal syncope is a common disorder and does not usually cause life-threatening situations. The term “malignant vasovagal syncope” is used to explain a rare unexplained syncope that is recurrent and can cause serious disability[16,17]. Because the patient recovered soon

after stopping tamsulosin and had no further severe events, malignant vasovagal syncope was excluded as the cause of her severe hypotension. Excluding all other possible causes and combined with the absence of an additional severe event, we concluded that tamsulosin was the reason for her symptoms.

Furthermore, considering her history of diabetes mellitus (DM), her shock might have been due to autonomic neuropathy. Diabetes-associated cardiovascular autonomic neuropathy affects the autonomic nerve that innervates the heart and blood vessels and can cause multi-organ failure[18]. However, autonomic neuropathy due to DM was less likely because her blood glucose level had been well-controlled.

Though no other such cases have been reported, use of tamsulosin could cause severe side effects in people with SCI. We focused on orthostatic hypotension and vasovagal symptoms as risk factors of severe adverse effects of tamsulosin in people with SCI. Cardiovascular complications, including orthostatic hypotension, are frequently seen in people with SCI and are often attributed to sympathetic nervous system disturbances, loss of supraspinal control, and peripheral α -adrenoreceptor hyperresponsiveness[19,20]. With disturbances in cardiovascular systems in people with SCI, adverse effects of tamsulosin are possible. In people with SCI suffering orthostatic hypotension and vasovagal symptoms, tamsulosin could affect BP based on underlying pathophysiology of orthostatic hypotension seen in SCI. Additionally, the duration of use of tamsulosin should be analyzed. Bird *et al*[6] showed that the incidence of severe hypotension increased during the first 8 wk after administering tamsulosin to people with BPH[6]. The patient in the presented case suffered severe hypotension after 9 days of treatment with tamsulosin. The phrase “first-dose phenomenon” could be applied with use of tamsulosin in patients with SCI as well as in patients with BPH[6].

There were some limitations in this case report. First, we tended to manage urinary retention too strictly when using tamsulosin. The patient was able to self-void, and residual urine was in the range of 160-200 mL. Though we could have managed her with self-voiding and timed CIC, considering her cervical myelopathy, we thought that strict management of urinary retention with tamsulosin was needed to prevent urinary tract infection and autonomic dysreflexia. Second, we could not perform urodynamic study because the patient refused. In general, urodynamic study should be performed and used as the basis for appropriate treatments to manage voiding difficulty of SCI patients. We should have persuaded the patient to proceed with the urodynamic study. Third, we did not examine hemoglobin A1c level of the patient. However, in DM patients, hemoglobin A1c level should be measured because it reflects the mean blood sugar over the previous weeks to months[21].

CONCLUSION

This is the first reported case of severe life-threatening hypotension induced by tamsulosin in an SCI patient. Hence, we report this case to increase awareness when administering tamsulosin for neurogenic bladder to patients with SCI. Additional studies should be performed in patients with SCI treated with tamsulosin to reveal possible severe side effects.

FOOTNOTES

Author contributions: Lee JY was the patient’s physiatrist, reviewed the literature, and contributed to manuscript drafting; Lee HS was the patient’s physiatrist and reviewed the literature; Park SB reviewed the literature and contributed to manuscript drafting; Lee KH was responsible for manuscript revision for important intellectual content; all authors issued final approval for the version to be submitted; The authors alone are responsible for the content and writing of the article.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), according to which the manuscript was prepared and revised.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: South Korea

ORCID number: Jae Young Lee 0000-0002-8881-154X; Ho Seok Lee 0000-0002-3186-6005; Si-Bog Park 0000-0001-8910-

2262; Kyu Hoon Lee 0000-0001-7372-5676.

S-Editor: Fan JR**L-Editor:** A**P-Editor:** Fan JR

REFERENCES

- 1 **Chapple C**, Andersson KE. Tamsulosin: an overview. *World J Urol* 2002; **19**: 397-404 [PMID: 12022708 DOI: 10.1007/s00345-002-0246-7]
- 2 **Michel MC**, Bressel HU, Goepel M, Rübber H. A 6-month large-scale study into the safety of tamsulosin. *Br J Clin Pharmacol* 2001; **51**: 609-614 [PMID: 11422021 DOI: 10.1046/j.0306-5251.2001.01388.x]
- 3 **Abrams P**, Amarengo G, Bakke A, Buczyński A, Castro-Diaz D, Harrison S, Kramer G, Marsik R, Prajsner A, Stöhrer M, Van Kerrebroeck P, Wyndaele JJ; European Tamsulosin Neurogenic Lower Urinary Tract Dysfunction Study Group. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. *J Urol* 2003; **170**: 1242-1251 [PMID: 14501734 DOI: 10.1097/01.ju.0000084623.65480.f8]
- 4 **Meyer LE**, Brown JN. Tamsulosin for voiding dysfunction in women. *Int Urol Nephrol* 2012; **44**: 1649-1656 [PMID: 22983886 DOI: 10.1007/s11255-012-0275-0]
- 5 **Zhang HL**, Huang ZG, Qiu Y, Cheng X, Zou XQ, Liu TT. Tamsulosin for treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. *Int J Impot Res* 2017; **29**: 148-156 [PMID: 28424499 DOI: 10.1038/ijir.2017.12]
- 6 **Bird ST**, Delaney JA, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. *BMJ* 2013; **347**: f6320 [PMID: 24192967 DOI: 10.1136/bmj.f6320]
- 7 **Kumar D**, Khan FA. Tamsulosin-induced severe hypotension during general anesthesia: a case report. *J Med Case Rep* 2010; **4**: 365 [PMID: 21083875 DOI: 10.1186/1752-1947-4-365]
- 8 **Snapper H**, Cheshire WP. Oral and intravenous hydration in the treatment of orthostatic hypotension and postural tachycardia syndrome. *Auton Neurosci* 2022; **238**: 102951 [PMID: 35123367 DOI: 10.1016/j.autneu.2022.102951]
- 9 **Bushkov FA**. [Orthostatic hypotension in patients with posttraumatic cervical myelopathy]. *Zh Nevrol Psikhiatr Im S S Korsakova* 2019; **119**: 9-13 [PMID: 31407676 DOI: 10.17116/jnevro20191190619]
- 10 **Gaitonde S**, Malik RD, Christie AL, Zimmern PE. Bethanechol: Is it still being prescribed for bladder dysfunction in women? *Int J Clin Pract* 2019; **73**: e13248 [PMID: 30112787 DOI: 10.1111/ijcp.13248]
- 11 **Diokno AC**, Koppenhoefer R. Bethanechol chloride in neurogenic bladder dysfunction. *Urology* 1976; **8**: 455-458 [PMID: 982732 DOI: 10.1016/0090-4295(76)90274-0]
- 12 **Kim YJ**, Kang SW, Lee JH, Cho JH. Marked elevation of procalcitonin level can lead to a misdiagnosis of anaphylactic shock as septic shock. *Int J Infect Dis* 2015; **37**: 93-94 [PMID: 26119856 DOI: 10.1016/j.ijid.2015.06.012]
- 13 **Mitaka C**. Clinical laboratory differentiation of infectious versus non-infectious systemic inflammatory response syndrome. *Clin Chim Acta* 2005; **351**: 17-29 [PMID: 15563869 DOI: 10.1016/j.cccn.2004.08.018]
- 14 **Balk RA**. Systemic inflammatory response syndrome (SIRS): where did it come from and is it still relevant today? *Virulence* 2014; **5**: 20-26 [PMID: 24280933 DOI: 10.4161/viru.27135]
- 15 **Bonanno FG**. Clinical pathology of the shock syndromes. *J Emerg Trauma Shock* 2011; **4**: 233-243 [PMID: 21769211 DOI: 10.4103/0974-2700.82211]
- 16 **Biffi M**, Boriani G, Sabbatani P, Bronzetti G, Frabetti L, Zannoli R, Branzi A, Magnani B. Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine. *Heart* 1997; **77**: 268-272 [PMID: 9093048 DOI: 10.1136/hrt.77.3.268]
- 17 **Maloney JD**, Jaeger FJ, Fouad-Tarazi FM, Morris HH. Malignant vasovagal syncope: prolonged asystole provoked by head-up tilt. Case report and review of diagnosis, pathophysiology, and therapy. *Cleve Clin J Med* 1988; **55**: 542-548 [PMID: 3067910 DOI: 10.3949/ccjm.55.6.542]
- 18 **Agashe S**, Petak S. Cardiac Autonomic Neuropathy in Diabetes Mellitus. *Methodist Debaquey Cardiovasc J* 2018; **14**: 251-256 [PMID: 30788010 DOI: 10.14797/mdcj-14-4-251]
- 19 **Claydon VE**, Steeves JD, Krassioukov A. Orthostatic hypotension following spinal cord injury: understanding clinical pathophysiology. *Spinal Cord* 2006; **44**: 341-351 [PMID: 16304564 DOI: 10.1038/sj.sc.3101855]
- 20 **Teasell RW**, Arnold JM, Krassioukov A, Delaney GA. Cardiovascular consequences of loss of supraspinal control of the sympathetic nervous system after spinal cord injury. *Arch Phys Med Rehabil* 2000; **81**: 506-516 [PMID: 10768544 DOI: 10.1053/mr.2000.3848]
- 21 **Saudek CD**, Brick JC. The clinical use of hemoglobin A1c. *J Diabetes Sci Technol* 2009; **3**: 629-634 [PMID: 20144304 DOI: 10.1177/193229680900300402]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

